Diamyd Medical - Developing precision therapies for type 1 diabetes

Press Releases

October 3, 2025

Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1...

Events & Mediawatch

October 10, 2025 Sweden

BioStock: Screening kan ändra spelplanen för typ 1-diabetes

Events & Mediawatch

October 8, 2025 Sweden

Rapportkommentar - Bokslutskommuniké

Events & Mediawatch

September 25, 2025 Sweden

LifeScience Sweden: Han är Diamyds nya CFO

Events & Mediawatch

September 24, 2025 Sweden

BioStock: Investing in Life Science

Events & Mediawatch

September 19, 2025 USA

Reclaim Your Rise Podcast: Episode 189

Company Presentation

July 15, 2025

Download PDF

We see a clear potential to establish Diamyd^® as the first precision immunotherapy that safely and effectively modifies the course of Stage 3 Type 1 Diabetes.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Year-End Report 24/25

	Dates for financial information and other events
	October 25 − October 27, 2025 Breakthrough T1D Mission Summit Mission Summit 2025, Miami, Florida
	November 5 − November 8, 2025 ISPAD 2025 Montreal, Canada
	November 13, 2025 Annual Report Annual Report 2025
	November 24 − November 26, 2025 Deutsches Eigenkapitalforum Frankfurt, Germany
	December 4, 2025 Annual General Meeting Annual General Meeting 2025
	January 28, 2026 Quarterly Report 1 Quarterly Report 1 2025/2026
	March 25, 2026 Quarterly Report 2 Quarterly Report 2 2025/2026
	June 24, 2026 Quarterly Report 3 Quarterly Report 3 2025/2026
	October 7, 2026 Year-end Report Year-end Report 2025/2026

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop Type 1 Diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in Type 1 Diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board

Manufacturing of GAD65 in Umeå

A facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden.

Diamyd Medical develops therapies for Type 1 Diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 537 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® is a disease-modifying investigational medicine in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in Type 1 Diabetes is being confirmed in the precision medicine Phase III trial DIAGNODE-3. Diamyd^® is also being evaluated in the prevention Phase II trial DiaPrecise.

Order GAD for preclinical research

ORDER

Share This Page

GAD PRODUCTS

Order GAD for preclinical research

the Phase 3 trial DIAGNODE-3

and other ongoing trials

Developing precision therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd^®

Press Releases

Events & Mediawatch

Events & Mediawatch

Events & Mediawatch

Events & Mediawatch

Events & Mediawatch

Financial Reports

Company Presentation

Calendar

The Story of Diamyd Medical

Manufacturing of GAD65 in Umeå

THE COMPANY

Diamyd Medical develops therapies for Type 1 Diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Diabetes

Products

Clinical Trials

Order GAD for preclinical research

ORDER

Annual Report

Contact Us

Subscribe

Follow Us

the Phase 3 trial DIAGNODE-3

and other ongoing trials

Developing precision therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd®

Company Presentation

Calendar

The Story of Diamyd Medical

THE COMPANY

Diamyd Medical develops therapies for Type 1 DiabetesThe share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Order GAD for preclinical research

Annual Report

Follow Us

with Diamyd^®

Diamyd Medical develops therapies for Type 1 Diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)